D&T Subcommittee Meeting Bil. 02/2019

posted Jul 1, 2019, 6:06 PM by Chong Ching Wern   [ updated Jul 1, 2019, 6:16 PM ]


No.

Drug Name

Decision

1)

Propafenone 150mg Tablet

(Rytmonorm)

Agreed to accept as Special Formulary.

2)

Flecainide 100mg Tablet

(Tambocor)

Rejected as Special Formulary.

Propafenone was accepted as Special Formulary for the same indication.

3)

Deferasirox 90mg Tablet

Deferasirox 360mg Tablet

(Exjade)

Rejected as Standard Formulary.

Suggest requestor to apply for extra funding from Jawatankuasa Pengurusan Kewangan dan Akaun (JPKA) for additional subsidy for five patients.

4)

Flurbiprofen 4mg Patch

(Acustop Cataplasma)

Rejected as Special Formulary.

Availability of Diclofenac Gel and Ketoprofen Gel in the UMMC formulary and readily available in retail pharmacies.

5)

Paroxetine 25mg CR Tablet

(Seroxat)

Agree to delete from the UMMC formulary.

To use generic option as first choice and was agreed by Psychiatric Team to switch to Apo-Paroxetine 20mg Tablet.

6)

Montelukast 4mg Tablet

(Singulair)

Agree to delete from the UMMC formulary.

Slow movement and stocks were expired. Availability of Montelukast 4mg Granules in the UMMC formulary.

7)

Telbivudine 600mg Tablet

(Sebivo)

Agree to delete from the UMMC formulary.

Company discontinuation.

8)

Tinzaparin 4500units Injection

(Innohep)

Agree to delete from the UMMC formulary.

Company discontinuation.

9)

Vitamin B (B1, B2, B6) Injection 

(Becolim)

Agree to delete from the UMMC formulary. 

Company discontinuation. Availability of Vitamin B and C Injection in the UMMC formulary.

10)

Olodaterol 2.5mcg Inhalation Solution 

(Striverdi Respimat)

Agree to delete from the UMMC formulary.

Company discontinuation. Availability of Spiriva Respimat and Spiolto Respimat in the UMMC formulary.

11)

Oxybutinin 5mg Tablet

(Voxytane)

Agree to delete from the UMMC formulary.

Company discontinuation and was agreed by Peadiatric Surgery Team.

12)

Dulaglutide 0.75mg Injection

Dulaglutide 1.5mg Injection

(Trulicity)

Rejected as Special Formulary.

Dulaglutide’s Cardiovascular Outcome Trial (CVOT) published: Dulaglutide reduced cardiovascular outcomes in patients with or without previous cardiovascular disease. 

Costs more than Liraglutide 1.2mg once daily (with CVOT) and Exenatide 2mg once weekly.



Disclaimer: 

For new drug request, physical stock availability will depend on procurement processes. 

Tender items will take about 3-6 months, non tender items will take about 1-3 months. 

Online formulary will be updated once physical stock is available or has depleted in UMMC Pharmacy.